![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1636045
Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå º¸°í¼ : ¹ÙÀÌ·¯½º Á¾·ùº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2025-2033³â)Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2025-2033 |
Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1¾ï 9,080¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 7¾ï 9,790¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 16.37%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇÏ°í ÀÖ½À´Ï´Ù.
Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á´Â ¹ÙÀÌ·¯½º¸¦ ÀÌ¿ëÇÏ¿© ¾Ï¼¼Æ÷¸¦ °¨¿°½ÃÄÑ Æı«ÇÏ´Â ¸é¿ªÄ¡·áÀÇ ÇÑ ÇüÅÂÀÔ´Ï´Ù. ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º, ´ºÄ³½½º´ ¹ÙÀÌ·¯½º, ¹é½Ã´Ï¾Æ ¹ÙÀÌ·¯½º, ¾Æµ¥³ë ¹ÙÀÌ·¯½º, ·¹¿À ¹ÙÀÌ·¯½º, ÇÇÄݷγª ¹ÙÀÌ·¯½º µî ´Ù¾çÇÑ Ãµ¿¬ ¹ÙÀÌ·¯½º¿Í À¯ÀüÀÚ ÀçÁ¶ÇÕ ¹ÙÀÌ·¯½º¸¦ »ç¿ëÇÕ´Ï´Ù. Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á´Â ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å°´Â À§Çè½ÅÈ£¸¦ È°¼ºÈ½ÃÄÑ °íÇüÁ¾¾ç, Èæ»öÁ¾, ÀýÁ¦ ºÒ°¡´ÉÇÑ º´º¯ÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç¥Àû Á¾¾ç ¼¼Æ÷¸¸À» °¨¿°½ÃÄÑ Æı«ÇÏ´Â ¹ÙÀÌ·¯½º¸¦ ÀÌ¿ëÇÏ¿© Á¾¾çÀ» ±ÙÀýÇÏ´Â µ¥¿¡µµ µµ¿òÀÌ µË´Ï´Ù. ÈÇпä¹ý¿¡ ºñÇØ Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á´Â µ¶¼ºÀÌ ¾ø°í, ¿ì¼öÇÑ È¿´ÉÀ» ³ªÅ¸³»¸ç, ¾Ï ȯÀÚÀÇ »ýÁ¸±â°£À» ¿¬Àå½Ãŵ´Ï´Ù. µû¶ó¼ º´¿ø, Áø·á¼Ò, ¾Ï ¿¬±¸±â°ü µî¿¡¼ Æø³Ð°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.
Àü ¼¼°è ¾Ï ¹ßº´·üÀÇ Áõ°¡´Â ½ÃÀå¿¡ ¹àÀº Àü¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. Á¾¾ç¿ëÇؼº ¹ÙÀÌ·¯½º Ä¡·á´Â °·ÂÇÑ Ç×Á¾¾ç Ư¼º°ú ÁÖº¯ Á¶Á÷¿¡ Çظ¦ ³¢Ä¡Áö ¾Ê°í Á¾¾çÀ» Á¤È®ÇÏ°Ô Ç¥ÀûÀ¸·Î »ï´Â ´É·ÂÀ¸·Î ÀÎÇØ ±³¸ð¼¼Æ÷Á¾, À¯¹æ¾Ï, Æó¾Ï, Àü¸³¼±¾Ï µî ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ç÷¾× ¾Ç¼º Á¾¾ç, ¸²ÇÁÁ¾, ¹éÇ÷º´, °ñ¼öÁ¾ µî ´Ù¾çÇÑ À¯ÇüÀÇ Èæ»öÁ¾ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü°úÀû °³ÀÔ, ¹æ»ç¼± ¿ä¹ý, ÈÇпä¹ý, ¸é¿ª¿ä¹ý µî ´Ù¾çÇÑ ¾Ï Ä¡·á·Î ÀÎÇÑ °Ç° ¾Ç¿µÇâ¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¿ì·Á°¡ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç츣Æ佺 ¹ÙÀÌ·¯½º, ¾Æµ¥³ë ¹ÙÀÌ·¯½º, ¹é½Ã´Ï¾Æ ¹ÙÀÌ·¯½º µî ÃÖÁ¾ ´Ü°è¿¡ ÀÖ°í ¿ì¼öÇÑ ½ÇÇè °á°ú¸¦ º¸ÀÌ°í ÀÖ´Â ¾Ï ¿ëÇØ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ÀÓ»ó ¿¬±¸ÀÇ ¼ö°¡ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ±× ¿Ü, ÷´Ü Ä¡·á ¹× »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾ÏÀÇ ´Ù¾çÇÑ ¿øÀο¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í Á¶±â Áø´ÜÀ» ÃËÁøÇϱâ À§ÇÑ ¿©·¯ Á¤ºÎ À̴ϼÅƼºêÀÇ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global oncolytic virus therapies market size reached USD 190.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 797.9 Million by 2033, exhibiting a growth rate (CAGR) of 16.37% during 2025-2033.
Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.
The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.
Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Adenovirus
Vaccinia Virus
Oncolytic Wild-Type Viruses
Reovirus
Newcastle Disease Virus
Vesicular Stomatitis Virus
Solid Tumors
Breast Cancer
Prostate Cancer
Lung Cancer
Glioblastoma
Melanoma
Hematological Malignancies
Lymphoma
Leukemia
Myeloma
Hospitals
Specialty Clinics
Cancer Research Institute
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.